Endo International PLC chart

Last update: 2022-12-29
Key statistics and financials
Revenue per share 11.89
Dividend & YieldN/A£ (N/A)
Beta 1.38
Market capitalization 229.29k
Operating cash flow 80.14M
ESG Scores unknown

Company description

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Sector: - Industry:

Financial Ratios
Quick Ratio1.49
Working Capital-0.57
Return On Equity0.49
Debt To Equity-6.47
Fixed Asset Ratio0.33
Fixed Interest Cover1.41

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -425.34M -525.75M -171.37M 84.39M
Total Cashflows From Investing Activities -17.9M -60.2M -624.87M -59.54M
Net Borrowings -39.37M 237.99M -96.68M -78.75M
Total Cash From Financing Activities -81.57M 204.6M -108.57M -105.48M
Change To Operating Activities -12.8M 11.37M -27.42M -34M
Issuance Of Stock 933k 4k 622k 622k
Net Income -1.03B -422.64M 183.94M -613.25M
Change In Cash 165.82M 243.55M -335.39M 246.31M
Effect Of Exchange Rate -1.98M 1.1M 654k 285k
Total Cash From Operating Activities 267.27M 98.05M 397.39M 411.05M
Depreciation 688.51M 612.86M 518.81M 88.93M
Change To Account Receivables 17.09M 19.16M -45.79M -82.05M
Other Cashflows From Financing Activities -37.76M -23.24M -3.85M -12.58M
Change To Netincome 986.78M 407.37M 26.75M 467.43M
Capital Expenditures -86.95M -67.69M -72.86M -80.65M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 185.83M 130.73M 153.81M 147.19M
Income Before Tax -938.83M -344.9M -26.52M -546.6M
Net Income -1.03B -422.64M 183.94M -613.25M
Selling General Administrative 646.04M 632.42M 670.65M 840.97M
Gross Profit 1.32B 1.35B 1.52B 1.78B
Ebit 483.53M 581.87M 691.52M 793.03M
Operating Income 483.53M 581.87M 691.52M 793.03M
Interest Expense -521.66M -538.73M -537.11M -562.94M
Income Tax Expense 22.93M 15.68M -273.98M 22.48M
Total Revenue 2.95B 2.91B 2.9B 2.99B
Cost Of Revenue 1.63B 1.57B 1.39B 1.21B
Total Other Income ExpenseNet -1.42B -926.78M -718.03M -1.34B
Net Income From Continuing Ops -961.77M -360.58M 247.46M -569.08M
Net Income Applicable To Common Shares -1.03B -422.64M 183.94M -613.25M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 10.63B 10.26B 9.91B 10.01B
Total Stockholder Equity -498.28M -866.54M -647.94M -1.24B
Other Current Liabilities 1.32B 868.98M 690.66M 880.82M
Total Assets 10.13B 9.39B 9.26B 8.77B
Common Stock 22k 23k 23k 23k
Other Current Assets 305.37M 247.46M 171.56M 124.11M
Retained Earnings -9.12B -9.55B -9.37B -9.98B
Treasury Stock -229.18M -219.04M -217.7M -216.4M
Cash 1.15B 1.45B 1.21B 1.51B
Total Current Liabilities 1.95B 1.46B 1.25B 1.63B
Other Stockholder Equity -229.18M -219.04M -217.7M -216.4M
Property, Plant, and Equipment 498.89M 556.57M 495.5M 431.54M
Total Current Assets 2.34B 2.59B 2.41B 2.71B
Net Tangible Assets -7.72B -7.03B -6.95B -6.8B
Net Receivables 519.65M 515.52M 578.3M 602.04M
Accounts Payable 96.02M 101.53M 94.41M 123.13M


Insider Transactions

Here are the insider transactions of stock shares related to Endo International PLC:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MALETTA MATTHEW JOSEPHD2022-03-30Officer34.41k
COLEMAN BLAISED2022-03-30Chief Executive Officer35.91k
BARRY PATRICK AD2022-03-30Officer16.96k
BRADLEY MARK TD2022-03-30Chief Financial Officer10.73k
MONTAGUE WILLIAM PStock Award(Grant) at price 0.00 per share.D2021-06-11Director47.92k
HYATT MICHAELStock Award(Grant) at price 0.00 per share.D2021-06-11Director47.92k
BARBERIO MARK GStock Award(Grant) at price 0.00 per share.D2021-06-11Director47.92k
COOKE SHANE MStock Award(Grant) at price 0.00 per share.D2021-06-11Director47.92k
HUTSON NANCY JStock Award(Grant) at price 0.00 per share.D2021-06-11Director47.92k
CHAO JENNIFER MStock Award(Grant) at price 0.00 per share.D2021-06-11Director47.92k
SMITH MARY CHRISTINEStock Award(Grant) at price 0.00 per share.D2021-06-11Director52.24k
CAMPANELLI PAUL VD2021-04-06Director368.3k
MALETTA MATTHEW JOSEPHD2021-04-06Officer66.98k
COLEMAN BLAISED2021-04-06Chief Executive Officer66.98k
BARRY PATRICK AD2021-04-06Officer29.23k
BOYLE JACK DD2021-04-06Officer12.65k
BRADLEY MARK TD2021-04-06Chief Financial Officer25.58k
MONTAGUE WILLIAM PSale at price 8.68 per share.D2021-03-15Director9.03k
COOKE SHANE MSale at price 8.65 per share.D2021-03-15Director17.29k
BARRY PATRICK AStock Award(Grant) at price 0.00 per share.D2021-03-05Officer68.85k
BRADLEY MARK TStock Award(Grant) at price 0.00 per share.D2021-03-05Chief Financial Officer71.98k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Endo International PLC. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Endo International PLC

Here is the result of two systematic investment strategies applied to Endo International PLC. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Endo International PLC

The following chart shows the equity curve of the two systematic investment strategies applied to Endo International PLC:

Endo International PLC automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Endo International PLC

This is the result of two momentum investment strategies applied to Endo International PLC. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Endo International PLC

The following chart shows all the entries opened by the momentum investment system on Endo International PLC:

Endo International PLC momentum entries
  • The first momentum investment strategy would give 62.44% of return on Endo International PLC. That represents 156.61£ of latent gain with 250.79£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Endo International PLC. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

62.44 %

Latent gain

156.61 £

Invested capital

250.79 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Endo International PLC

The following chart shows the equity curve of the two momentum strategies applied to Endo International PLC:

Endo International PLC momentum equity

Note: the dividends potentially given by Endo International PLC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Endo International PLC

The following chart shows the employed capital evolution of the two momentum strategies on Endo International PLC since the beginning:

Endo International PLC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Endo International PLC

Buy the dip entry openings on Endo International PLC

Endo International PLC

The performance achieved by the robo-advisor on Endo International PLC is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Endo International PLC stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Endo International PLC, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Endo International PLC

The following chart shows the result of the investment strategy applied to Endo International PLC:

Endo International PLC

Note: the dividends potentially given by Endo International PLC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Endo International PLC

The following chart shows the employed capital evolution since the beginning of the investment strategy on Endo International PLC:

Endo International PLC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Endo International PLC

In this section, I will compare the three previous investment strategies applied to Endo International PLC.

Equity curve comparison on Endo International PLC

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Endo International PLC investment strategy comparison

Employed capital comparison on Endo International PLC

Endo International PLC investment comparison

Performance comparison on Endo International PLC

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 62.44% 156.61£ 250.79£ 1561.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Endo International PLC:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Endo International PLC and the other stocks. There may be false positives or some missing correlated stocks. If the price of Endo International PLC does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Endo International PLC
Country Ireland
City Dublin
Address Minerva House
Phone 353 1 268 2000
Website www.endo.com
FullTime employees 3103
Industry
Sector
Exchange XLON
Ticker 0Y5F.XLON
Market www.londonstockexchange.com

Endo International PLC ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown